ARTICLE | Top Story
Aptalis files for $500 million IPO
December 27, 2013 1:06 AM UTC
Gastrointestinal company Aptalis Holdings Inc. (Mont-Saint-Hilaire, Quebec) filed to raise up to $500 million in an IPO underwritten by Goldman Sachs; JPMorgan; Barclays; and Evercore. Aptalis markets nine products, including Carafate sucralfate suspension to treat active duodenal ulcers and Zenpep pancrelipase to treat exocrine pancreatic insufficiency. For the fiscal year ended Sept. 30, Aptalis reported revenues of $687.9 million. ...